目錄:MedChemExpress LLC>>生化試劑>> Sotorasib | MCE
CAS | 2296729-00-3 | 純度 | 99.94% |
---|---|---|---|
分子量 | 560.59 | 分子式 | C??H??F?N?O? |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 5 mg |
貨號 | HY-114277 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
CAS No. : 2296729-00-3
產(chǎn)品活性:Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors.
研究領(lǐng)域:GPCR/G Protein
作用靶點(diǎn):Ras
In Vitro: In cellular assays, Sotorasib (AMG-510) covalently modifies KRAS G12C and inhibits KRAS G12C signaling as measured by phosphorylation of ERK1/2 (p-ERK) in all KRAS p.G12C-mutant cell lines.
Sotorasib (AMG-510; 1-10 μM; 72 hours) also potently impairs cellular viability in both NCI-H358 and MIA PaCa-2 with IC50≈0.006 μM and 0.009 μM, respectively. Non-KRASG12C lines are insensitive to Sotorasib (IC50>7.5 μM).
In Vivo: In preclinical tumor models, Sotorasib (AMG-510) rapidly and irreversibly binds to KRAS G12C, providing durable suppression of the mitogen-activated protein kinase (MAPK) signaling pathway. Sotorasib (orally; once daily) is capable of inducing tumor regression in mouse models of KRAS G12C cancer.
相關(guān)產(chǎn)品:Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Kinase Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Ferroptosis Compound Library | Orally Active Compound Library | Chemical Probe Library | Glutamine Metabolism Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | LC-2 | KRAS G12C inhibitor 54 | MRTX1133 | AZA1 | RBC10 | CFL-137 | Deltarasin hydrochloride | BDP9066 | CCG-100602 | KRAS inhibitor-4 | KRas G12R inhibitor 1 | MRTX0902 | KRAS G12C inhibitor 25 | Antitumor agent-60 | KRAS G12C inhibitor 30 | KRas G12C inhibitor 1 | Spiclomazine hydrochloride | GGTI-286 hydrochloride | 6H05 | AZD4625 | SOS1-IN-6 | Antineoplaston A10 | Opnurasib | K-Ras-IN-1 | BI-0474 | Diazepinomicin | K20 | BQU57 | KRAS G12D inhibitor 12 | KRas G12C inhibitor 3
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物 | 寡核苷酸 | 抗體 | 點(diǎn)擊化學(xué)
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實(shí)驗(yàn)驗(yàn)證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機(jī)構(gòu)建立了長期的合作。
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)